Accentia pharmaceuticals news

A group of investors led by Hopkins Capital Group LLC formed Accentia, which will develop therapeutics for respiratory and critical care oncology indications. Accentia combines Hopkins acquisitions Analytica and TEAMM, plus a majority interest in BioVest International. The new company markets Respi-TANN carbetapentane/pseudoephedrine and the Histex line of products to treat cough, cold and allergy. Accentia also will market recently approved pain drug Xodol hydrocodone-acetaminophen combination and co-promote dermatology products Alcortin and Novacort with Primus Pharmaceuticals Inc. (Scottsdale, Ariz.). Through its BioVest subsidiary, Accentia will provide cell culture systems for biologics. ...